Summary
- Shares of Bausch Health are down over 70% this year.
- Underwhelming earnings and developments around the Xifaxan patent have been the primary drivers of underperformance vs. the broader equity market.
- However, Bausch Health expects its Xifaxan patent to hinder generic entry in the U.S. until 2029 despite approval.
- In the midst of Bausch Health's stock at 25-year lows, activist investor Carl Icahn was recently joined by billionaire hedge fund manager John Paulson.
- I'll explain why I am cautiously optimistic about the long-term prospects of Bausch Health if its debt can be reduced over the next three years.
For further details see:
Bausch Health: Things To Consider Before Investing